

Hector Chinoy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/713848/publications.pdf>

Version: 2024-02-01

199
papers

7,017
citations

81900

39
h-index

69250

77
g-index

204
all docs

204
docs citations

204
times ranked

6323
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1955-1964.	0.9	754
2	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	10.7	394
3	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017, 69, 2271-2282.	5.6	391
4	The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1345-1349.	0.9	291
5	Autoantibodies to a 140 kDa protein in juvenile dermatomyositis are associated with calcinosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1807-1814.	6.7	206
6	Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. <i>Rheumatology</i> , 2007, 47, 324-328.	1.9	186
7	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. <i>Journal of Autoimmunity</i> , 2019, 101, 48-55.	6.5	184
8	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.9	183
9	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014, 53, 213-222.	1.9	177
10	Phenotype Standardization for Statin-Induced Myotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 470-476.	4.7	166
11	Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1621-1625.	0.9	161
12	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST). <i>Journal of Autoimmunity</i> , 2019, 101, 1-10.	1.5	130
13	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.9	127
14	Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.9	116
15	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017, 3, e000507.	3.8	115
16	Genome-wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. <i>Arthritis and Rheumatism</i> , 2013, 65, 3239-3247.	6.7	113
17	In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. <i>Arthritis Research and Therapy</i> , 2006, 8, R13.	3.5	110
18	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. <i>Genes and Immunity</i> , 2015, 16, 470-480.	4.1	103

#	ARTICLE	IF	CITATIONS
19	HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. <i>Rheumatology</i> , 2007, 46, 1786-1791.	1.9	102
20	Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 961-965.	0.9	100
21	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Neurology</i> , The, 2019, 18, 834-844.	10.2	91
22	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	5.6	90
23	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 996-1002.	0.9	81
24	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	2.0	77
25	Statin-induced necrotizing myositis - A discrete autoimmune entity within the statin-induced myopathy spectrum. <i>Autoimmunity Reviews</i> , 2013, 12, 1177-1181.	5.8	74
26	Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 795-798.	0.9	74
27	Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 862-868.	0.9	71
28	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	1.9	69
29	The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. <i>Rheumatology</i> , 2019, 58, 650-655.	1.9	66
30	Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1383-1386.	0.9	59
31	The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 3247-3254.	6.7	56
32	Defining cancer risk in dermatomyositis. Part I. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 451-455.	1.3	54
33	Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies. <i>Frontiers in Immunology</i> , 2019, 10, 848.	4.8	54
34	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	5.6	52
35	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 602-611.	0.9	51
36	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.9	49

#	ARTICLE	IF	CITATIONS
37	Tumour necrosis factor- \hat{A} single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2007, 46, 1411-1416.	1.9	44
38	Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the <scp>UK</scp> Clinical Practice Research Datalink. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1353-1361.	4.7	44
39	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. <i>Rheumatology</i> , 2018, 57, 1896-1907.	1.9	43
40	HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2009, 48, 1213-1217.	1.9	41
41	Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	5.6	41
42	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. <i>Neurobiology of Aging</i> , 2016, 47, 218.e1-218.e9.	3.1	40
43	Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment. <i>Clinical Medicine</i> , 2017, 17, 322-328.	1.9	39
44	COVID-19 and myositis - unique challenges for patients. <i>Rheumatology</i> , 2021, 60, 907-910.	1.9	39
45	Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 561-565.	1.3	38
46	Recent advances in the immunogenetics of idiopathic inflammatory myopathy. <i>Arthritis Research and Therapy</i> , 2011, 13, 216.	3.5	38
47	Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2010, 49, 1699-1705.	1.9	37
48	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2022, 42, 23-29.	3.0	37
49	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	1.9	37
50	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019, 58, 889-896.	1.9	35
51	Successful use of tocilizumab in a patient with psoriatic arthritis. <i>Rheumatology</i> , 2013, 52, 1728-1729.	1.9	33
52	Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 970-973.	0.9	32
53	Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2018, 57, 1041-1046.	1.9	32
54	The role of microRNAs in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2015, 27, 608-615.	4.3	31

#	ARTICLE	IF	CITATIONS
55	Genetic association study of NF- κ B genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2012, 51, 794-799.	1.9	30
56	GATM gene variants and statin myopathy risk. <i>Nature</i> , 2014, 513, E1-E1.	27.8	30
57	Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021, 185, 646-648.	1.5	30
58	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	3.8	29
59	Rituximab-associated Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E41-E43.	1.9	28
60	Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. <i>Rheumatology</i> , 2021, 60, 3398-3403.	1.9	27
61	Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 535-541.	5.8	26
62	Genotyping of immune-related genetic variants identifies <i>TYK2</i> as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1750-1752.	0.9	25
63	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis. <i>Neurology</i> , 2021, 96, e1595-e1607.	1.1	25
64	The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. <i>Cardiovascular Endocrinology and Metabolism</i> , 2021, 10, 125-131.	1.1	25
65	Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?. <i>Current Opinion in Rheumatology</i> , 2004, 16, 707-713.	4.3	24
66	The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 86-91.	2.4	24
67	[¹⁸ F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 657-662.	0.9	24
68	Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 295-302.	3.4	22
69	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. <i>Rheumatology</i> , 2019, 58, 468-475.	1.9	22
70	Wegener's granulomatosis and rheumatoid arthritis overlap. <i>British Journal of Rheumatology</i> , 2002, 41, 588-589.	2.3	21
71	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	3.4	21
72	New developments in genetics of myositis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 651-656.	4.3	21

#	ARTICLE	IF	CITATIONS
73	Long-term strength and functional status in inclusion body myositis and identification of trajectory subgroups. <i>Muscle and Nerve</i> , 2020, 62, 76-82.	2.2	21
74	An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. <i>Current Opinion in Rheumatology</i> , 2009, 21, 588-593.	4.3	20
75	Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. <i>Arthritis Research and Therapy</i> , 2019, 21, 147.	3.5	20
76	Serum alanine aminotransferase elevations correlate with serum creatine phosphokinase levels in myositis. <i>Rheumatology</i> , 2006, 45, 487-488.	1.9	19
77	Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2013, 25, 735-741.	4.3	19
78	COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. <i>Rheumatology</i> , 2022, 62, 65-76.	1.9	19
79	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	13.7	18
80	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. <i>PLoS ONE</i> , 2019, 14, e0218115.	2.5	18
81	A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies. <i>BMC Rheumatology</i> , 2019, 3, 41.	1.6	18
82	Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 611-616.	4.3	18
83	Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle. <i>Frontiers in Genetics</i> , 2021, 12, 702547.	2.3	18
84	Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2018, 30, 606-613.	4.3	17
85	Pitfalls in the diagnosis of myositis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101486.	3.3	17
86	The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. <i>Rheumatology</i> , 2016, 55, 2277-2278.	1.9	16
87	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1- β autoantibodies in adult patients with myositis. <i>Arthritis Research and Therapy</i> , 2018, 20, 117.	3.5	16
88	Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. <i>BMC Rheumatology</i> , 2020, 4, 28.	1.6	16
89	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. <i>Rheumatology</i> , 2020, 59, 1026-1030.	1.9	16
90	Association of an MHC Class II Haplotype with Increased Risk of Polymyositis in Hungarian Vizsla Dogs. <i>PLoS ONE</i> , 2013, 8, e56490.	2.5	16

#	ARTICLE	IF	CITATIONS
91	Monocyte chemotactic protein-1 single nucleotide polymorphisms do not confer susceptibility for the development of adult onset polymyositis/dermatomyositis in UK Caucasians. <i>Rheumatology</i> , 2006, 46, 604-607.	1.9	15
92	Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky035.	0.7	15
93	A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. <i>Rheumatology</i> , 2016, 55, 2131-2137.	1.9	14
94	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	1.9	14
95	Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatology</i> , 2016, 43, 169-176.	2.0	14
96	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. <i>Indian Journal of Rheumatology</i> , 2022, 17, 188.	0.4	14
97	Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: a qualitative study. <i>Rheumatology</i> , 2016, 55, 1047-1052.	1.9	13
98	MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies. <i>BMC Rheumatology</i> , 2020, 4, 25.	1.6	12
99	Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2008, 48, 591-592.	1.9	11
100	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1530-1534.	2.4	11
101	Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223249.	0.5	11
102	Monitoring disease activity and damage in adult and juvenile idiopathic inflammatory myopathy. <i>Current Opinion in Rheumatology</i> , 2020, 32, 553-561.	4.3	11
103	Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis. <i>Clinical Rheumatology</i> , 2021, 40, 231-238.	2.2	11
104	Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey. <i>Clinical Medicine</i> , 2014, 14, 95-96.	1.9	10
105	Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms. <i>Rheumatology</i> , 2019, 58, 375-376.	1.9	10
106	The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients. <i>Rheumatology</i> , 2020, 59, 1626-1631.	1.9	10
107	Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. <i>Journal of Rheumatology</i> , 2020, 47, 1204-1208.	2.0	10
108	Limb girdle muscular dystrophy R12 (LGMD 2L, anoctaminopathy) mimicking idiopathic inflammatory myopathy: key points to prevent misdiagnosis. <i>Rheumatology</i> , 2022, 61, 1645-1650.	1.9	10

#	ARTICLE	IF	CITATIONS
109	Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods – a qualitative study. <i>BMC Rheumatology</i> , 2020, 4, 47.	1.6	9
110	Analysis of human total antibody repertoires in TIF1 β autoantibody positive dermatomyositis. <i>Communications Biology</i> , 2021, 4, 419.	4.4	9
111	Time for a “joint” approach?. <i>British Journal of Dermatology</i> , 2013, 168, 683-684.	1.5	7
112	SAT0052 – Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A UK-Based Prospective Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 608.1-608.	0.9	7
113	Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians. <i>Rheumatology International</i> , 2020, 40, 2047-2055.	3.0	7
114	Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort. <i>Arthritis and Rheumatology</i> , 2022, 74, 342-352.	5.6	7
115	Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 880-884.	0.8	7
116	Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 938-940.	0.9	6
117	Strategies for Evaluating Idiopathic Inflammatory Myopathy Disease Susceptibility Genes. <i>Current Rheumatology Reports</i> , 2014, 16, 446.	4.7	5
118	Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease. <i>Reumatologia</i> , 2016, 1, 35-37.	1.1	5
119	Scalp Necrosis Associated with Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2016, 374, e6.	27.0	5
120	A systematic review and meta-analysis of mycobacterial infections in patients with idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2022, 61, 3521-3533.	1.9	5
121	The role of protein aggregation in the pathogenesis of inclusion body myositis.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 414-424.	0.8	5
122	Academic training in rheumatology in 2009: a UK trainee survey. <i>Clinical Medicine</i> , 2011, 11, 434-437.	1.9	4
123	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016, 18, 156.	3.5	4
124	Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria. <i>Rheumatology</i> , 2019, 58, 2331-2333.	1.9	4
125	Response to: “Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future” by Wang et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218712.	0.9	4
126	Can machine learning unravel the complex IIM spectrum?. <i>Nature Reviews Rheumatology</i> , 2020, 16, 299-300.	8.0	4

#	ARTICLE	IF	CITATIONS
127	Polymyositis and dermatomyositis. , 2013, , 1009-1020.		4
128	A Literature Review of Eosinophilic Fasciitis with an Illustrative Case. Current Rheumatology Reviews, 2017, 13, 113-120.	0.8	4
129	Adult idiopathic inflammatory myopathies. Medicine, 2022, 50, 70-75.	0.4	4
130	Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. Rheumatology, 2022, 61, 4845-4854.	1.9	4
131	Idiopathic inflammatory myopathies. Medicine, 2018, 46, 140-145.	0.4	3
132	Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibodyâ€“positive dermatomyositis: Reply. Rheumatology, 2019, 58, 2073-2074.	1.9	3
133	In Pursuit of an Effective Treatment: the Past, Present and Future of Clinical Trials in Inclusion Body Myositis. Current Treatment Options in Rheumatology, 2021, 7, 63-81.	1.4	3
134	Ustekinumab for psoriatic arthritis: close to the PSUMMIT?. Lancet, The, 2013, 382, 748-749.	13.7	2
135	Editorial. Current Opinion in Rheumatology, 2013, 25, 726-728.	4.3	2
136	Response to: â€“Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaâ€“™ by Cavagna et al. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-212382.	0.9	2
137	211â€“fIs HLA-B27 a predictor of treatment response to biologics in psoriatic arthritis?. Rheumatology, 2019, 58, .	1.9	2
138	The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. Dermatology and Therapy, 2019, 9, 373-381.	3.0	2
139	The avalanche of antirheumatic therapy and COVID-19 vaccinations. Rheumatology, 2021, 60, 3490-3491.	1.9	2
140	Polymyositis and dermatomyositis. , 2013, , 1009-1020.		2
141	Inflammatory Arthropathy in the Elite Sports Athlete. Current Sports Medicine Reports, 2021, 20, 577-583.	1.2	2
142	Diagnosis of spinal tuberculosis in an Asian patient with unexplained chronic back pain. Rheumatology, 2021, , .	1.9	2
143	Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health and Disease, 0, , .	1.5	2
144	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. Journal of Dermatological Treatment, 2014, 25, 61-62.	2.2	1

#	ARTICLE	IF	CITATIONS
145	Effect of immunogenicity on efficacy of long-term treatment of rheumatoid arthritis with adalimumab. <i>Lancet, The</i> , 2014, 383, S60.	13.7	1
146	Drug-specific risk, and associated factors, of vasculitis-like events in patients exposed to tumour necrosis factor alpha inhibitor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Lancet, The</i> , 2016, 387, S55.	13.7	1
147	Simple tool in a complex case: use of the nailfold capillaroscopy. <i>Kidney International</i> , 2016, 89, 1168.	5.2	1
148	Pheochromocytoma in association with focal dermatomyositis. <i>Rheumatology</i> , 2016, 55, 953-954.	1.9	1
149	Serum muscle damage markers in the idiopathic inflammatory myopathies: quantifying disease activity and identifying cardiac involvement. <i>Neuromuscular Disorders</i> , 2017, 27, S39-S40.	0.6	1
150	Rheumatology training in Poland vs. United Kingdom. <i>Reumatologia</i> , 2017, 3, 120-124.	1.1	1
151	Quality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. <i>Rheumatology</i> , 2018, 57, .	1.9	1
152	Relapsing polychondritis of the nose and lower respiratory tract. <i>Rheumatology</i> , 2021, 60, e41-e43.	1.9	1
153	Hand-held dynamometry may provide a valid and objective method of muscle strength quantification in adult inflammatory myopathy: results from clinical practice in a tertiary centre. <i>Rheumatology</i> , 2021, 60, .	1.9	1
154	Perspectives on glucocorticoid usage in patients with adult inflammatory myopathy. <i>Clinical Rheumatology</i> , 2021, 40, 4977-4982.	2.2	1
155	CHIPPING AWAY AT POLYMYOSITIS: A RETROSPECTIVE REVIEW AT A TERTIARY MYOSITIS CENTRE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1111-1112.	0.9	1
156	The perils of myositis mimickers with illustrative case reports. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 366-372.	0.8	1
157	The effect of the Covid-19 pandemic on illness perceptions of psoriasis and the role of depression: Findings from a cross-sectional study. <i>Skin Health and Disease</i> , 0, , .	1.5	1
158	Use of Anti-200/100 Antibody in the Evaluation of Statin Induced Myositis: Experience of a UK Based Tertiary Myositis-Referral Centre. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A645.1-A645.	0.9	0
159	Gene and Gene-Environment Interactions in Defining Risk and Spectrum of Phenotypes in Idiopathic Inflammatory Myopathies. , 2014, , 115-132.		0
160	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. <i>British Journal of Dermatology</i> , 2014, 170, 995-996.	1.5	0
161	Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 151.1-151.	0.9	0
162	Exploring new mechanisms of weakness-induction, further dissection of clinical phenotypes and identification of new biomarkers in the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2015, 27, 577-579.	4.3	0

#	ARTICLE	IF	CITATIONS
163	O10.â€fRisk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, , .	1.9	0
164	11.â€fA comparative study of the clinical features of dermatomyositis in child and in adult patients where the Anti-Mi-2 antibody is present. Rheumatology, 2017, 56, .	1.9	0
165	PO203â€f...Assessing disease activity and cardiac involvement in myositis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A65.2-A65.	1.9	0
166	i169â€fResearch update. Rheumatology, 2018, 57, .	1.9	0
167	O23â€fThe incidence of adult idiopathic inflammatory myopathies at a UK specialist neuromuscular centre: a ten-year epidemiology study. Rheumatology, 2018, 57, .	1.9	0
168	THU0013â€f...Downregulation of microRNA may contribute to activation of the interferon signalling pathway in the idiopathic inflammatory myopathies. , 2018, , .		0
169	i117â€fMICHAEL MASON WINNER 2018. Rheumatology, 2018, 57, .	1.9	0
170	122â€fHigh burden of immunosuppressant use in undifferentiated connective tissue disease: results from the Lupus Extended Autoimmune Phenotype Study (LEAP) cohort. Rheumatology, 2018, 57, .	1.9	0
171	169â€fSecukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. Rheumatology, 2018, 57, .	1.9	0
172	O67â€fA regional survey and audit of service provision for giant cell arteritis. Rheumatology, 2018, 57, .	1.9	0
173	253â€fSignatures of microbial and autoantibody epitopes in idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	1.9	0
174	117â€fAnti-TIF-1 antibody positivity is associated with a five-fold increase in cancer risk in the idiopathic inflammatory myopathies. Rheumatology, 2018, 57, .	1.9	0
175	219â€fConverting patients with chronic myositis from maintenance intravenous immunoglobulin therapy to rituximab in England: a potential saving of Â£1.7 million per year. Rheumatology, 2019, 58, .	1.9	0
176	221â€fQuantitative strength profiling in inclusion body Myositis: faster deterioration in males and positive associations with functional assessment tools. Rheumatology, 2019, 58, .	1.9	0
177	222â€fInvestigating the sensitivity and specificity of the myositis profile-4 EUROLINE assay. Rheumatology, 2019, 58, .	1.9	0
178	E086â€fClinical and serological features of increased interferon-alpha activity in an unselected connective tissue disease cohort. Rheumatology, 2019, 58, .	1.9	0
179	220â€fDiscrepancy between solid-phase immunoassays and immunoprecipitation in detecting anti-TIF1 gamma in patients with myositis. Rheumatology, 2019, 58, .	1.9	0
180	O33â€fEarlier cancer diagnosis after myositis onset is associated with improved long term survival: results from UK, French and Czech cohorts. Rheumatology, 2020, 59, .	1.9	0

#	ARTICLE	IF	CITATIONS
181	P72â€fMuscle weakness affects function differently in males and females in inclusion body myositis: providing results for focused clinical care and clinical trial design. Rheumatology, 2020, 59, .	1.9	0
182	P253â€fSecukinumab provides sustained improvements in tender and swollen joint counts: 5year results from the Phase 3 FUTURE 2 study. Rheumatology, 2020, 59, .	1.9	0
183	P254â€fSecukinumab provides rapid and sustained improvement in joint tenderness and swelling in patients with PsA: 2-year results from the Phase 3 FUTURE 5 study. Rheumatology, 2020, 59, .	1.9	0
184	Focal hamstring muscle oedema and atrophy post-anterior cruciate ligament reconstruction mimicking focal myositis. Rheumatology, 2021, 60, 984-985.	1.9	0
185	P156â€fMyositis flares are associated with reduced work productivity and fewer hours worked: illustration of the future potential of digital healthcare solutions in rheumatic diseases. Rheumatology, 2021, 60, .	1.9	0
186	P192â€fSecukinumab provides rapid and sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 2-year results from the Phase 3 FUTURE 5 study. Rheumatology, 2021, 60, .	1.9	0
187	POS0288â€f...A KEY TIF1Î³ EPTOPE MAY FACILITATE THE IDENTIFICATION OF PATIENTS AT HIGHEST RISK OF CANCER ASSOCIATED MYOSITIS. Annals of the Rheumatic Diseases, 2021, 80, 369.2-370.	0.9	0
188	The challenges of antirheumatic therapy and travel-associated infections. Rheumatology, 2021, , .	1.9	0
189	OP0148â€f...A validation of the 2017 eular/acr idiopathic inflammatory myopathies classification criteria in an expert-defined single-centre ten year incident cohort. , 2018, , .		0
190	SP0041â€f...Win session: what is new in the treatment of myositis?., 2018, , .		0
191	FRIO455â€f...Increasing incidence of adult idiopathic inflammatory myopathies: a ten-year uk epidemiological study. , 2018, , .		0
192	Antiâ€f3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy. Journal of Clinical Rheumatology, 2020, 26, e230-e231.	0.9	0
193	Myositis Basics/Who Gets Myositis. , 2020, , 7-15.		0
194	SAT0631-HPRâ€f...WHEN CAN I STOP MY STEROIDS? THE PATIENT PERSPECTIVE ON GLUCOCORTICOID USAGE IN ADULT INFLAMMATORY MYOPATHY. Annals of the Rheumatic Diseases, 2020, 79, 1275.1-1276.	0.9	0
195	OP0094â€f...EULAR-ACR 2019 CLASSIFICATION CRITERIA FOR SLE: CAN WE CLASSIFY USING LABORATORY TESTS ALONE?. Annals of the Rheumatic Diseases, 2020, 79, 62.2-62.	0.9	0
196	The perils of myositis mimickers with illustrative case reports.. Clinical and Experimental Rheumatology, 2022, 40, 366-372.	0.8	0
197	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	0
198	The role of protein aggregation in the pathogenesis of inclusion body myositis.. Clinical and Experimental Rheumatology, 2022, 40, 414-424.	0.8	0

#	ARTICLE	IF	CITATIONS
199	P222â€fClinical features of extra-muscular disease in dermatomyositis and anti-synthetase syndrome patients with skin involvement classified by presence of disease-specific autoantibodies: results from the EuroMyositis registry. <i>Rheumatology</i> , 2022, 61, .	1.9	0